New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance
AiCuris Announces that its Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe
Positive opinion for EU just after U.S. market authorization
AiCuris’ Licensee MSD Received U.S. FDA Approval of PREVYMIS™ (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients
First antiviral drug developed from AiCuris’ pipeline to receive market approval
AiCuris AIC649 Showed Potential for Functional Cure
AiCuris to Present Pre-clinical Data on AIC649 against Chronic Hepatitis B at the AASLD-The Liver Meeting
Data generated in an NIH-funded study being conducted at Georgetown University.
AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial (LipP 1) with Topical Pritelivir for the Treatment of recurrent Labial Herpes
The final patient has been treated in the clinical phase 2 efficacy and safety study LipP 1 evaluating topical pritelivir, a small molecule helicase-primase inhibitor, for the treatment of recurrent labial herpes (cold sores)
AiCuris Granted Fast Track Designation by U.S. FDA for Oral Pritelivir for Treatment of HSV Infections in Immunocompromised Adults
Fast track is a process designed to facilitate the development, expedite the review and accelerate the approval process of drugs to treat serious conditions and fill an unmet medical need, with the purpose of getting important new drugs to patients sooner
AiCuris Initiates U.S. Clinical Phase 2 Trial with Oral Pritelivir
Opening of the first site in its clinical phase 2 study, PRIOH-1
AiCuris selects Mercachem as preferred medicinal chemistry partner
AiCuris Announces Publication of Phase 2 Clinical Trial Results of Investigational Anti-Herpes Simplex Virus Agent Pritelivir in JAMA
Study results clearly supported pritelivir to be more effective than alacyclovir for suppression of herpes simplex virus (HSV) genital shedding in patients with frequent recurrences
AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
Program supported by the Innovative Medicines Initiative
AiCuris Announces Start of LipP 1
First Subject Enrolled in the Clinica Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
AiCuris Announces U.S. NIH Support of Preclinical Study with AIC649
AiCuris hosts mini-symposium of experts to discuss challenges and breakthroughs in anti-infectives at BIO-Europe® 2016
AiCuris celebrates its 10th Anniversary hosting a Mini-Symposium on Challenges and Breakthroughs of Anti-infective Therapies at the BIO-Europe® 2016
AiCuris’ licensee MSD says Letermovir, an investigational prophylactic therapy against HCMV in bone marrow transplant patients, met Primary Endpoint in Pivotal Phase 3 Study
AiCuris with Case Study in Going Public “Biotechnologie 2016”
AiCuris Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus, Achieves Primary Endpoint in Clinical Phase I Study
Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug
AiCuris Initiates Clinical Development for Topical Pritelivir, a Highly Active Inhibitor for the Treatment of Herpes Simplex Virus
AiCuris’ AIC649 Shows Potential to Induce Functional Cure of Chronic Hepatitis B in Preclinical Study
AIC649 is an inactivated parapoxvirus ovis (iPPVO) particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses.
J.P. MORGAN Healthcare Conference
Meet AiCuris at J.P. Morgan 34th Annual Healthcare Conference 2016 January 11-14 in San Francisco, CA, USA.
Holger Zimmermann elected as board member of BioDeutschland
The annual meeting of BioDeutschland took place in Hannover on Monday, 5th of October. Part of the meeting was also the election of a new board for the next two years.
Release of BEAM Position Paper
The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) today announces the release of its position paper.
IMI: Start of epidemiological study
The IMI-funded COMBACTE-MAGNET-consortium announced the start of a retrospective epidemiological study in autumn 2015
AiCuris’ Chair of the Scientific Advisory Board, Prof. Ruebsamen-Schaeff honored with “IUPAC Award”
Prof. Helga Rübsamen-Schaeff, founding CEO and as of March Chair of the Scientific Advisory Board of Wuppertal-based Biotech AiCuris has been honored with the "IUPAC 2015 Distinguished Women in Chemistry or Chemical Engineering Award".
AiCuris & the BEAM Alliance
AiCuris is one of the founding members of the newly launched alliance of Biotechs of Europe innovating in Anti-Microbial Resistance”, called the BEAM Alliance.
AiCuris strengthens its management / AiCuris stärkt sein Management
Dr. Manickam Rangaraju joined AiCuris on 1st May 2015 as new Head of Development, responsible for all preclinical and clinical activities of the company. Already one month before Dr. Alexander Birkmann had taken over the position as Head of Research.
COMBACTE-MAGNET - ANOTHER NEW PROJECT TO REVITALISE ANTIBIOTIC DEVELOPMENT
Press release of the University of Utrecht on behalf of COMBACTE-MAGNET
Today 33 European academic partners and 5 pharmaceutical companies are launching a new project, COMBACTE-MAGNET, under the IMI antimicrobial resistance research programme New Drugs 4 Bad Bugs (ND4BB).
If you have a media enquiry or further questions regarding public relation activities at AiCuris please contact:
Katja Woestenhemke
Management Assistant
AiCuris Anti-infective Cures GmbH
Friedrich-Ebert-Str. 475
42117 Wuppertal
Phone: +49 (0)202 317 63 - 0
Fax: +49 (0)202 317 63 - 1177
E-Mail: press(at)aicuris.com